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Abstract
Among the dysfunctions and pathologies associated with sepsis, the underlying molecular mechanisms of sepsis-
induced acute lung injury (ALI) are poorly understood. Endothelin (ET)-1, a potent vasoconstrictor and pro-
inflammatory peptide, is known to be involved in the pathogenesis of ALI in a rat model of sepsis. Here, we 
investigated whether landiolol hydrochloride, an ultra-short-acting β-blocker, plays a crucial role in ameliorating 
and attenuating LPS-induced ALI through modulation of the ET-1 system. Male Wistar rats at 8 weeks of age 
were ad-ministered with either saline or lipopolysaccharide (LPS) for three hours (3 h) and some of the LPS-
administered rats were continuously treated with landiolol for 3 h. ALI was induced by LPS, including levels of 
both circulatory and pulmonary TNF-α and IL-6 but [PaO2]was significantly decreased. LPS also induced a 
significant increase in levels of pulmonary ET-1 and ET-A receptor, but levels of ET-B receptor, which has 
vasodilating effects, were remarkably diminished. Further, LPS administration upregulated the pulmonary 
expression of HIF-1α.Finally, the treatment of LPS-administered rats with landiolol for 3 h ameliorated and 
prevented ALI, normalized the altered levels of pulmonary ET-1 and ET-A receptors. Landiolol also induced 
significant down-regulation of ET-B receptor in lung tissues in the early hours (phase) of sepsis. However, 
Landiolol treatment had no effect on the up-regulated inflammatory mediators (TNF-α, IL-6) in both plasma and 
lung tissues during sepsis, and expression of pulmonary HIF-1α also remained unchanged after landiolol 
treatment. Collectively, these data led us to conclude that landiolol may ameliorate sepsis-induced ALI via the 
pulmonary ET system.
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1 Introduction
Sepsis is a critical life threatening conditio
compasses pathologic infection and physiolo
lectively known as systemic inflammatory 
[1]. The mortality from sepsis and the assoc
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infiltration [7], pulmonary hypertension, e
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of units [3]. To date, the pathogenesis of sepsis and its progression to mu
tiple organ dysfunction syndrome (MODS) and the associated septi
shock are poorly understood and thus have been the subject of invest
gations in the last several decades.
Acute lung injury (ALI) is a well-known and frequent complicatio
of sepsis, and causes a significant number of sudden deaths (mortality
and morbidity [4–6]. For this reason, patients with ALI/ARDS account fo
a significant proportion of the intensive care unit (ICU) case load. A
and acute respiratory distress syndrome (ARDS), the severe form  severe hypoxia pulmonary 
dema and deteriorated gas 
isk factor for ALI and ARDS 
erlying the pathogenesis of
 understood. We do know 
us vasoconstrictor and pro-
inflammatory peptide [9,10], is actively involved in the pathogenesis of
sepsis and the sepsis-associated organ dysfunction, as well as the asso-
ciated complications [11], as evidenced by data from recent studies.
Specifically, plasma levels of ET-1 are elevated in various sepsis animal
models, including septic patients [12–15] and a clear correlation has
been observed between ET plasma levels and morbidity/mortality in
septic patients. These observations implicate ET in the pathogenesis of
septic shock in human [16,17]. Further, ET-1 likely has a direct role in
the development and subsequent severity of ALI by increasing the pres-
sure of pulmonary microvasculature during the first phase or hours of
sepsis [18,19]. Interestingly, endothelin blocker, namely tezosentan,
ameliorates pulmonary hypertension, lung edema, cardiac dysfunction,
and arterial hypoxemia in an ovine model of endotoxin-induced lung
injury [20]. In contrast, intravenous infusion of ET-1 causes an elevation
in pulmonary artery pressure and edema [21], implying a direct role of
ET-1 in the pathogenesis of lung injury.
Landiolol hydrochloride, an ultra-short-acting and highly cardio-se-
lective beta-1 blocker, with a half-life of 4min, has been used in treating
several acute medical disorders, including arrhythmias, during heart
surgery [22], acute myocardial infarction [23], acute decompensated
heart failure [24], and refractory electrical storm [25]. Ultra-short-acting
β-blockers, such as landiolol, can influence heart rate but exert minimal
effect on cardiac function. Besides, the potential effects of landiolol on
rhythm control, landiolol also plays a protective role against ALI in a
rat model of lipopolysaccharide (LPS)-induced systemic inflammation,
which is associated with a reduction in high mobility group box 1
(HMGB-1) [26]. Very recently, we have demonstrated that landiolol is
effective in improving acute liver injury of sepsis through the modula-
tion of TNF (tumor necrosis factor-alpha)-α [27]. In addition, we have
also shown that ET-1 is highly upregulated in kidney and heart tissues
in LPS-administered rats [28,29] and landiolol has inhibitory effects on
the upregulated levels of ET-1 in both of these tissues. However, it is
not known whether landiolol will equally exert protective effects in
lung tissues during sepsis through the alteration of the ET-1 system. In-
deed, in our previous study we have already reported elevated ET-1
levels in lung tissues during sepsis [30].
In the present study, we investigated whether landiolol hydrochlo-
ride, an ultra- short-acting β-blocker, can play an important role in at-
tenuating LPS-induced ALI through the modulation of pulmonary ET-1.
2. Materials and methods
Male Wistar rats (200–250 g, 8 weeks old) were used in all experi-
ments in the current study. Sepsis was induced by the intra-peritoneal
(IP) administration of bacterial LPS from Escherichia coli 055: B5 (15
mg/kg), dissolved in sterile saline, as described previously [31–33]. A
dose 15 mg/kg of LPS has been shown to induce morphological injures
in lung [34] as shown in our dose response study.
The total number of rats used in all the experiment was 45, which
was randomized into three groups, namely: Group 1 (control, n =
15), group 2 (LPS, n = 15) and group 3 (LPS + landiolol hydrochloride,
n = 15). For group 1, sterile saline (2 ml/body) was administered at
time 0 h and then the rats were killed after 3 h (control group). For
group 2, LPS at a dose of 15 mg/kg was administered at time 0 h, and
then the rats were killed after 3 h (sepsis group). In group 3, landiolol
hydrochloride was administered intravenously (100 μg/kg/min) for
15 min non-stop before LPS administration (landiolol treated sepsis
group). The dose for landiolol was found to be theminimal dose for nor-
malizing the LPS-induced hyperdynamic state in the acute (early) phase
(hours) of sepsis, as reported in our past study [28].
Nembutal (sodium pentobarbital, IP, 80 mg/kg body weight, rou-
tinely used in our lab) was used to kill all the rats at 3 h, at the end of
the experimental protocol. Blood gas analysis was also performed in
the current study. The blood samples were collected from a polypropyl-
ene tube catheter inserted into the left carotid artery for blood gas anal-
ysis, and then lung tissues were carefully harvested, snap-frozen inliquid nitrogen, and stored at−80 °C. All animals received proper care
and the experimental procedures were approved by the Animal Care
and Use Committee of University of Tsukuba prior to the study.
2.1. Measurements of hemodynamic parameters
Hemodynamic parameters were measured using a previously opti-
mized methodology from our lab [27–35]. Briefly, rats were anesthe-
tized with isoflurane inhalation (1.5%, 1 l/min) and a microtip
pressure transducer catheter (SPC-320, Millar Instruments, Houston,
TX, USA)was inserted into the left carotid artery at the end of the exper-
imental protocol. Arterial blood pressure andheart rate (HR)weremon-
itored with a pressure transducer (model SCK-590, Gould, Ohio, USA)
and recorded with the use of a polygraph system (amplifier, AP-601G,
Nihon Kohden, Tokyo, Japan; Tachometer, AT-601G, Nihon Kohden;
and thermal-pen recorder, WT-687G, Nihon Kohden).
2.2. Echocardiography
Echocardiographywasperformedusing a Vevo 2100high-frequency
ultrasound system (VisualSonics, Inc., Ontario, Canada), which includes
an integrated rail system for consistent positioning of the ultrasound
probe [36] at the end of the protocol. The fur from the chest was shaved
with an electrical clipper and a gel. The animals were then connected to
an electrocardiogram (ECG). An optimal parasternal long axis (LAX)
cine loop (i.e. visualization of both the mitral and aortic valves, and
maximum distance between the aortic valve and the cardiac apex) of
N1000 frames/s was acquired using the ECG-gated kilohertz visualiza-
tion technique. The probe was then rotated 90° and positioned 6 mm
below the mitral annulus. Three parasternal short-axis (SAX) M-mode
sequences were stored. Percent fractional shortening (% FS) was calcu-
lated in the M-mode image as FS = (EDD − ESD) / EDD, where EDD
and ESD are the end-diastolic and end-systolic diameters, respectively.
2.3. Lung wet-to-dry weight ratio
Lung tissueswere harvested, blotted dry andweighed in order to de-
termine the weight of the lung in the wet state and the wet-to-dry
weight ratio was calculated, as follows: the lung tissues were weighed;
wrapped loosely in aluminum foil; dried in an oven at 80 °C for 24 h;
and weighed again. Then the ratio lung wet-to-dry weight ratio was
calculated.
2.4. Histopathology examination
After tissue harvest, the lungs were fixed in 4% buffered formalin so-
lution, dehydrated, embedded in paraffin, and then sliced into 5-mm-
thick sections to evaluate lung micro-morphological injury. After
deparaffinization, tissue sectionswere stained using standard hematox-
ylin and eosin (HE) staining method.
2.5. Enzyme-linked immunosorbent assay
The concentration of each respective protein/peptide, as described
below under the plasma/serum and pulmonary tissue extracts section,
was determined using the following kits: serum and lung levels of
tumor necrosis factor alpha (TNF-α) and ET-1; plasma levels of IL-6 (R
& D Systems, Minneapolis, MN), according to the manufacturer's proto-
col. These kits are already validated for themeasurement of rat samples
in our lab.
2.6. RNA preparation and real-time quantitative polymerase chain reaction
Total RNA samples from lung tissues were isolated using the acid
guanidinium thiocyanatephenol chloroform extraction with RNeasy
(Qiagen, Tokyo, Japan). After RNA isolation, quantification and DNase I
Table 1
Blood gas analysis parameters.
Parameters Control LPS LPS + landiolol
pH 7.39 ± 0.01 7.37 ± 0.02 7.38 ± 0.01
PaO2 (Torr) 102.8 ± 2.2 84.2 ± 4.7⁎ 102.4 ± 3.9♯
PaCO2 (Torr) 40.2 ± 1.4 40.9 ± 2 37.2 ± 2
Base excess (mmol/l) 0.5 ± 0.5 −2.8 ± −0.7⁎ −3.9 ± 0.7⁎
Lactate (mmol/l) 1.4 ± 0.1 2.8 ± 0.2⁎ 2 ± 0.1♯
HCO3– (mmol/l) 25.3 ± 0.5 21.4 ± 0.7⁎ 20.7 ± 0.8⁎
Data are mean ± SE. Abbreviations: LPS; lipopolysaccharide.
⁎ p b 0.05 vs. control.
♯ p b 0.05 vs. LPS.
Table 2
Hemodynamics and echocardiogram.
Parameters Control LPS LPS + landiolol
Systolic BP (mm Hg) 125.6 ± 3.2 93.2 ± 6.6⁎ 98.5 ± 5⁎
Diastolic BP (mm Hg) 99.8 ± 3.1 72.3 ± 5.8⁎ 75.5 ± 4.8⁎
Heart rate (bpm) 468.7 ± 19 501.2 ± 16.2⁎ 439.9 ± 6.5♯
Fractional shortening (%) 40.3 ± 1.3 45.1 ± 1.2⁎ 41.2 ± 1♯
Data are mean ± SE. Abbreviations: BP; blood pressure; LPS; lipopolysaccharide.
⁎ p b 0.05 vs. control.
♯ p b 0.05 vs. LPS.treatment, RNA was reverse transcribed to cDNA using Omniscript RT
and the first-strand cDNA synthesis kit (Qiagen). The reaction was per-
formed at 37 °C for 60 min.
The mRNA expression levels of target genes were analyzed by real-
time quantitative PCR using TaqMan probe and an ABI Prism 7700 se-
quence detector (PerkinElmer Applied Biosystems, Foster, CA). The
gene-specific primers and TaqMan probes were synthesized from Prim-
er Express version 1.5 software (PerkinElmer), according to the pub-
lished cDNA sequences for each gene, as previously described [32,37].
The PCR mixture (25 μl total volume) consisted of forward and reverse
primers for each gene (PerkinElmer) at 450 nM each, FAM-labeled
primer probes (PerkinElmer) at 200 nM, and TaqMan Universal PCR
Master Mix (PerkinElmer). Each PCR amplification was performed in
triplicate as follows: 1 cycle at 95 °C for 10 min and 40 cycles at 94 °C
for 15 s and 60 °C for 1 min. The quantitative values of target mRNAs
were normalized by glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA, because GAPDH mRNA expressions were more stable
among all the samples than other internal controls, such as β-actin
and 18S ribosomal RNA.
Primers and probes are as follows:
TNF-α forward: 5′-CCAGGAGAAAGTCAGCCTCCT-3′,
TNF-α reverse: 5′-TCATACCAGGGCTTGAGCTCA-3′, and
TNF-α probe: 5′-AGAGCCCTTGCCCTAAGGACACCCCT-3′;
IL-6 forward primer: 5′-ACAGCCACTGCCTTCCCTAC-3′,
IL-6 reverse: 5′-TCTCATTTCCAAGATCTCCC-3′, and
IL-6 probe: 5′-CACAGAGGATACCACCCACA-3′;
Hypoxia-inducible factor-1 alpha (HIF-1α) forward: 5′-
CTATGGAGGCCAGAAGAGGGTAT-3′,
HIF-1α reverse: 5′-CCCACATCAGGTGGCTCATAA-3′, and
HIF-1α probe: 5′-AGATCCCTTGAAGCTAG-3′,
ET-1 forward: 5′-TCTACTTCTGCCACCTGGACAT-3′;
ET-1 reverse: 5′-GAAGGGCTTCCTAGTCCATACG-3′, and
ET-1 probe: 5′-CATCTGGGTCAACACTCC-3′;
ET-A forward: 5′-GAATCTCTGCGCTCTCAGTGT-3′,
ET-A reverse: 5′-GAGACAATTTCAATGGCGGTAATCA-3′, and
ET-A probe: 5′-CAGGAAGCCACTGCTCT-3′;
ET-B forward: 5′-GCTGGTGCCCTTCATACAGA-3′,
ET-B reverse: 5′-CTTAGAGCACATAGACTCAACACTGT-3′, and
ET-B probe: 5′-ATCCCCACAGAAGCCT-3′;
GAPDH forward: 5′-GTGCCAAAAGGGTCATCATCTC-3′,
GAPDH reverse: 5′-GGTTCACACCCATCACAAACATG-3′, and
GAPDH probe: 5′-TTCCGCTGATGCCCC-3′.
2.7. Statistical analysis
The results were expressed as mean± SE, and for parametric distri-
bution, analysis of variance test was used. For non-parametric distribu-
tion, Kruskal-Wallis test, followed by Steel-Dwass for multiple
comparisonswas used. A p b 0.05was considered statistically significant
for all parameters.
3. Result
3.1. Blood gas analysis results
Table 1 shows the data of blood gas analysis in the current experi-
mental setting. pH was not significantly different among the three
groups (Table 1). Arterial PaO2 was significantly decreased in LPS-ad-
ministered rats compared to control group and landiolol treatment sig-
nificantly increased the levels of arterial PaO2 in septic rats (Table 1).
However, arterial PaCO2 was not significantly changed among the
three groups. Blood lactate concentrations were elevated with LPS ad-
ministration and 3 h treatment with landiolol partly normalized the el-
evated levels of lactate in LPS-administered rats (Table 1). HCO3– andbase excess were not significantly changed among the three groups
(Table 1).
3.2. Hemodynamic changes in current experiments:
We assessed the hemodynamic parameters in the rats after LPS ad-
ministration. As shown in Table 2, both the levels of the systolic and di-
astolic blood pressure were significantly lower at 3 h after LPS
administration compared to that of the control group andwas unaffect-
ed by landiolol treatment. Landiolol significantly decreased the elevated
heart rate in LPS-administered animals (Table 2). % FS was also signifi-
cantly increased (hyperkinetic) in LPS-administered group compared
to that of control group, and a 3 h long treatment of LPS-administered
rats with landiolol significantly reversed the elevated % FS (Table 2).
3.3. Morphological evaluation
In the LPS-administered group, lung tissues showed thickening of al-
veolar, congestion formation and infiltration by neutrophils, but (these
morphological abnormalities) were absent in the lung of the control
group (Fig. 1A). Landiolol treatment for 3 h significantly improved the
lung congestion in septic rats (Fig. 1A).
Wet-to-dry weight ratio of lung tissue was calculated in each study
group in the present experiment. In the LPS-administered septic
group, pulmonary wet-to-dry weight ratios were significantly higher
compared to that of the control group and a 3 h treatment of septic an-
imals with landiolol significantly normalized the pulmonarywet-to-dry
ratio (Fig. 1B).
3.4. Evaluation of expression of ET-1 system in lung tissue
Levels of ET-1 peptidewere also evaluated in the current experimen-
tal setting (Fig. 2A). ET-1 peptide expressionwas significantly increased
in the lung tissue (about 2-fold) after LPS administration compared to
the control group and landiolol treatment for 3 h significantly normal-
ized the elevated levels of pulmonary ET-1 peptide in septic rats
(Fig. 2A).While levels of pulmonary ET-1 in septic ratswas greatly ame-
liorated following the 3 h treatment by landiolol, landiolol treatment
failed to normalize the elevated levels of plasma ET-1 in septic rats
(Table 3). Prepro ET-1 mRNA levels were also elevated in lung tissue
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Fig. 1. A; Morphological findings by hematoxylin and eosin staining (HE) in lung tissues in control rats, 3 h after lipopolysaccharide (LPS) administration, and 3 h after LPS plus landiolol
hydrochloride administration.Magnification, ×320. B; Pulmonarywet-to-dryweight ratio in control rats, 3 h after lipopolysaccharide (LPS) administration, and 3 h after LPS plus landiolol
hydrochloride administration. Wet-to-dry weight ratios were determined for each experimental group. Values are mean ± SE (n = 5). * p b 0.05 vs. control, # p b 0.05 vs. LPS.in the LPS-administered group compared to the control group. Howev-
er, landiolol treatment normalized the elevated levels of prepro ET-1
mRNA in septic lung tissues (Fig. 2B). Moreover, ET-A receptor mRNA
expression in lung tissue was also elevated in the LPS administration
group compared to the control group, and landiolol treatment0
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Fig. 2. Peptide and mRNA expression levels of ET-1 (A and B),mRNA expression levels of ET-A
treated 3 h LPS-administered rats. ET-1 peptide was measured by ELIZA. mRNA expression l
mean ± SE (n = 15). * p b 0.05 vs. control, # p b 0.05 vs. LPS.normalized the elevated levels of ET-A receptormRNA (Fig. 2C) in septic
rats. In contrast, ET-B receptor mRNA expression in lung tissue signifi-
cantly decreased in the LPS administration group compared to the con-
trol group, and landiolol treatment failed to normalize the decreased
levels of ET-B receptor mRNA in septic pulmonary tissues (Fig. 2D).0
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(C), ET-B (D) receptors inlung tissues in control, 3 h LPS-administered rats, and landiolol
evel was determined by Real Time PCR. The control was normalized as 100%. Values are
Table 3
Plasma tumor necrosis factor (TNF)-α, endothelin-1 (ET-1) and interleukin-6 (IL-6) levels.
Control LPS LPS + landiolol
TNF- (plasma, pg/ml) 15.7 ± 7# 180 ± 40⁎ 184.3 ± 30.1⁎
ET-1 (plasma, pg/ml) 3.8 ± 0.4# 34 ± 3.3⁎ 32.5 ± 3.3⁎
IL-6 (plasma, pg/ml) 18.3 ± 1.9# 29 ± 3.3⁎ 26.7 ± 3.7⁎
Data are mean ± SE. Abbreviations: LPS; lipopolysaccharide.
⁎ p b 0.05 vs. control.
# p b 0.05 vs. LPS.3.5. Evaluation of expression levels of inflammatory cytokine (TNF-alpha
and IL-6)
Both the upregulated plasma levels of potential inflammatory cyto-
kines, TNF-α and IL-6 were unchanged with the treatment of landiolol
in septic rats (Table 3). We also evaluated the expression patterns of
mRNA and protein of TNF-α, the key inflammatory cytokine in lung tis-
sues during sepsis. Levels of both protein and mRNA (TNF-α) were sig-
nificantly higher in septic lungs compared to the control group and a 3 h
treatment of septic rats with landiolol could not normalize the elevated
levels of TNF in lungs (Fig. 3A, B). In the current experimental setting,
the expression levels of IL-6, another highly potent inflammatory cyto-
kine, had parallel expression pattern as TNF-α (Fig. 3C), which was up-
regulated in LPS-administered rats and was unchanged following
landiolol treatment.3.6. Evaluation of expression levels of HIF-1α
In addition, to clarify whether LPS administration induces any hyp-
oxic condition in pulmonary tissues, we examined the mRNA expres-
sion levels of HIF-1α in lung tissue in present study. HIF-1α mRNA
expression levels were also increased in the LPS administration group0
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Fig. 3.mRNA and protein expression levels of TNF-α (A and B), and mRNA expression levels o
treated 3 h LPS-administered rats. TNF-α protein was measured by ELIZA. mRNA expression
mean ± SE (n = 15). * p b 0.05 vs. control, # p b 0.05 vs. LPS.in lung tissues, but landiolol treatment did not normalize the elevated
pulmonary levels of HIF-1α (Fig. 3D).
4. Discussion
The present study is the first to demonstrate the normalization of el-
evated ET levels in rat pulmonary tissues by an ultrashort acting beta
blocker (landiolol hydrochloride) during the early stages (hours) of sep-
sis. Further, this phenomenon (of landiolol on pulmonary ET-1 level) is
also accompanied by an improvement in the morphology of the septic
lung tissues. Here, we also show that pre-treatment of LPS-adminis-
tered rats with landiolol for 3 h normalized both the diminished levels
of PaO2 and enhanced levels of blood lactate in early sepsis. In contrast,
these observed pulmonary ameliorations (molecular and morphologi-
cal) in septic rats induced by landiolol are not associatedwith alteration
in levels of inflammatory cytokines (TNF-α, IL-6) and hypoxia marker
(HIF-1) under the current experimental setting.
A previous study has reported that LPS increases heart rate and % FS
in rats 3 h post administration and that if these (septic) animals are
treated with landiolol these altered conditions (HR and % FS) are nor-
malized [28,29]. It is interesting that while landiolol was able to de-
crease % FS and HR in septic rats, as reported previously, it (landiolol)
had no significant effect on systolic and diastolic blood pressure under
the current experimental setting. In fact, landiolol's effect on blood pres-
sure was lesser than esmolol, an ultra- short-acting β-blocker [38,39]. It
is likely that landiolol's ability to attenuate the LPS-induced
hyperdynamic state in septic rats may be linked to its (landiolol) partial
normalization of elevated blood lactate concentrations in early sepsis.
The present study demonstrates landiolol's ability to improve PaO2
during the early phase (hours) of sepsis in rats, as well as reduction of
congestion and normalization of thewet-to-dry ratio in lungs compared
to the untreated group. These findings are significant since LPS has been
shown to induce edema formation, infiltration of interstitial tissue by0
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f IL-6 (C), HIF-1α (D) in lung tissues in control, 3 h LPS-administered rats, and landiolol
level was determined by Real Time PCR. The control was normalized as 100%. Values are
neutrophils, and reduction of alveolar spaces in lungs, 12 h post-treat-
ment [40] and, importantly, these (same)morphological injuries dimin-
ished after administration of landiolol [26]. Thus, based on the current
data, we speculate that landiolol is equally effective in eliminating
acute septic-induced pulmonary tissue injuries through the reduction
of congestion, and, ultimately, leads to a decrease in pulmonary wet-
to-dry weight ratio and improvement in arterial PaO2.
ET-1 is a potent vasoconstrictor and pro-inflammatory peptide and
has previously been implicated in the pathogenesis of sepsis and sep-
sis-induced MODS [41,42]. Therefore, the present data, showing an in-
crease in the plasma levels of ET-1, are consistent with data obtained
from earlier studies [35] from our lab and others [16,17,43]. This ob-
served increase in levels of plasma ET-1 in septic animals may be due
to a combination of enhanced ET-1 synthesis, as well as impairment in
ET clearance in renal and pulmonary tissues [16]. ETs is also known to
play an important role in the pathogenesis of sepsis-induced ALI and
vascular failure [44] and for this reason ET blockers have been shown
to have a protective effect in ALI [45–49] and MODS in sepsis. Because
of these biological effects ETs have attracted significant research interest
in the development of novel therapeutic and diagnostic tools for sepsis
and other systemic inflammatory response syndromes (SIRS) and disor-
ders [12,50,51,52]. In our present study, we also found the elevated ET-1
level in lung tissues at 3 h after LPS administration at hyperdynamic
state in septic rats as consistent to past studies [30,35]. Lastly, although
levels of pulmonary ET-1 were found to be elevated during the early
phases (hours) of sepsis, its two receptors, ET-A and –B were differen-
tially expressed, i.e., levels of ET-A receptor were up regulated while
that of ET-B receptor were down regulated in lung tissue of septic rats.
These differential expression patterns (of ET receptors) in septic lung
were consistent with data from past studies [30,35].
The present study is the first time to demonstrate the amelioration
of an altered ET system and ET-A but not ET-B in lung tissue of septic
rats following a 3 h treatment of landiolol. We intend to examine in
depth the specific mechanisms underlying the differential effects of
landiolol on the expression of pulmonary ET receptor subtypes in future
using genetically altered/manipulated experimental animals, such as
the ET receptor knockout mice. In wrapping up, we speculate that
landiolol may normalize the altered ET-1 system using a similar path-
way or mechanism as the non-selective ET receptor antagonist,
bosentan [45], and it (landiolol) may also lead to the repair of lung inju-
ry in ALI in rat models, as demonstrated in the current study. However,
future studies are required to provide more data that supports our cur-
rent speculation.
Landiolol has been shown to be effective in preventing ALI in LPS ad-
ministered rat through the attenuation of an inflammatory marker,
HMGB-1 [26], as well in repairing lung injury in the early phases
(hours) of sepsis. Surprisingly, landiolol could not normalize the up reg-
ulated levels of pulmonary TNF-α and IL-6, two potential pro-inflam-
matory cytokines, back to baseline levels in septic rats. Based on these
currentfindings, it appears that the observed reversal effects of landiolol
on the elevated levels of ET-1 in pulmonary tissue does not depend on
the expression of TNF-α and IL-6 in septic rats. In contrast, following
landiolol treatment, the liver tissue of septic rats gets repairs during
the acute phase of liver injury and the up regulated levels of hepatic
TNF-α are normalized in the same experimental setting as in the cur-
rent study [27]. Thus it can be concluded that landiolol-induced repair
in organ injury during the acute phase of sepsis involves the normaliza-
tion of differential organ-specific signaling pathways. It is interesting to
note that in both of our studies (current and past study [27]), landiolol
failed to normalize the up regulated levels of plasma TNF-α, while
exerting differential effects on the levels of TNF-α in various organs of
septic rats. Further, although elevated HIF-1α has been shown to be
normalized in kidney tissues of septic rats, in addition to the ameliora-
tion of the up regulated levels of renal ET-1 by landiolol treatment
[28], the reversal effects of landiolol on the up regulated levels of pulmo-
nary ET-1 andHIF-1α had a different outcome in the present study fromthat of the renal tissues. The LPS-induced elevated levels of HIF-1α in
lung tissue demonstrated by the present study may imply the presence
of hypoxia. Future studies are undoubtedly essential in dissecting the
organ-specific effects of landiolol on various signaling pathways in sep-
tic rats, including the very early stages of sepsis. Of note, no significant
change in blood pressure of LPS-administered rats was observed after
landiolol treatment in the current study. These findings imply that the
normalization of the elevated levels of pulmonary ET-1 in sepsis by
landiolol is independent of blood pressure changes. Mechanistic studies
in future are essential in exploring and uncovering the underlying
mechanism of the current findings and in shedding more insights on
the potential protective effects that landiolol may exert on the lung in
early sepsis.
5. Conclusion
The present study demonstrates that landiolol hydrochloride, a se-
lective ultra-short-acting β-blocker, ameliorates lung injury in a rat
model during early sepsis. Landiolol possibly exerts such an effect
through the suppression of elevated levels of pulmonary ET-1 but not
levels of TNF-α and HIF-1α. These current findings may create news
areas to explore beneficial clinical and preventive applications of
landiolol in sepsis-induced multiple organ dysfunction syndrome, par-
ticularly in the acute phase of lung injury.
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